Hong Kong Stock Exchange

Bragar Eagel & Squire, P.C. Is Investigating Corcept, Hannon Armstrong, NIO, and Generac and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, August 6, 2022 - 2:00am

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Corcepts stock price fell $3.71 per share, or 16.91%, to close at $18.23 per share on December 8, 2021.
  • For more information on the Generac investigation go to: https://bespc.com/cases/GNRC
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Alibaba Group Appoints Two Independent Directors with Enhanced Corporate Governance

Retrieved on: 
Thursday, August 4, 2022 - 1:15am

The new appointments demonstrate the Companys commitment to corporate governance excellence and diversity at the board level.

Key Points: 
  • The new appointments demonstrate the Companys commitment to corporate governance excellence and diversity at the board level.
  • Following these appointments, the Companys board currently consists of twelve directors, including seven independent directors.
  • The new independent board member appointments are part of Alibabas ongoing enhancement of our corporate governance.
  • I am delighted to join Alibaba, with its mission to make it easier to do business with anyone, anywhere.

How Digital Domain Helped Reinvent ‘Ms. Marvel’s’ Powers for the MCU

Retrieved on: 
Wednesday, August 3, 2022 - 6:02pm

That gave the production a little more flexibility when adapting her powers for a live-action audience, and allowed the showrunners to work with Oscar and Emmy-winning VFX studio, Digital Domain , to reinvent Ms.

Key Points: 
  • That gave the production a little more flexibility when adapting her powers for a live-action audience, and allowed the showrunners to work with Oscar and Emmy-winning VFX studio, Digital Domain , to reinvent Ms.
  • Marvels abilities were going to change for her live-action debut, but everyone involved still wanted to honor the comics, said Aladino Debert, VFX supervisor for Digital Domain.
  • With Kamran beginning to lose control, Digital Domain was tasked with showing the damaging effects of his powers.
  • In 2018, Digital Domain acquired one of Chinas VR hardware equipment pioneers and leaders - VR Technology Holdings Ltd, Shenzhen (3Glasses).

IMAX and Cineworld Expand Longstanding Partnership with Agreement for Upgraded and New IMAX Locations Worldwide

Retrieved on: 
Wednesday, August 3, 2022 - 2:15pm

NEW YORK, Aug. 3, 2022 /PRNewswire/ -- Cineworld and IMAX Corporation (NYSE: IMAX) today announced an expansion of their longstanding partnership, under which 52 IMAX locations across Cineworld's worldwide footprint will be upgraded or opened by 2026. Cineworld and IMAX had previously contracted for 47 new or upgraded IMAX® systems and under the new agreement will add an additional five new IMAX with Laser systems across the UK and Europe. Under the agreement, Cineworld Leicester Square in London, Regal Irvine Spectrum in California, and Regal UA Sheepshead Bay in New York City will all feature IMAX with Laser.

Key Points: 
  • With Five New IMAX with Laser Systems, Cineworld Now Plans to Upgrade or Open a Total of 52 IMAX Systems across its Worldwide Footprint by 2026
    NEW YORK, Aug. 3, 2022 /PRNewswire/ -- Cineworld and IMAX Corporation (NYSE: IMAX) today announced an expansion of their longstanding partnership, under which 52 IMAX locations across Cineworld's worldwide footprint will be upgraded or opened by 2026.
  • Cineworld and IMAX had previously contracted for 47 new or upgraded IMAX systems and under the new agreement will add an additional five new IMAX with Laser systems across the UK and Europe.
  • Cineworld currently operates the most IMAX locations in Europe, and the two companies enjoy a longstanding partnership spanning nearly twenty-five years.
  • IMAX, IMAX Dome, IMAX 3D, IMAX 3D Dome, Experience It In IMAX, The IMAX Experience, An IMAX Experience, An IMAX 3D Experience, IMAX DMR, DMR, Filmed For IMAX, IMAX LIVE, IMAX Enhanced, IMAX nXos and Films to the Fullest, are trademarks and trade names of the Company or its subsidiaries that are registered or otherwise protected under laws of various jurisdictions.

Bright Scholar Completes Redemption of its Remaining Outstanding 7.45% Senior Notes Due 2022

Retrieved on: 
Wednesday, August 3, 2022 - 11:00am

FOSHAN, China, Aug. 3, 2022 /PRNewswire/ -- Bright Scholar Education Holdings Limited ("Bright Scholar," the "Company," "we" or "our") (NYSE: BEDU), a global premier education service company, today announced that it has redeemed all of its outstanding senior notes matured (the "Redemption") on July 31, 2022 (the "Maturity Date").

Key Points: 
  • FOSHAN, China, Aug. 3, 2022 /PRNewswire/ -- Bright Scholar Education Holdings Limited ("Bright Scholar," the "Company," "we" or "our") (NYSE: BEDU), a global premier education service company, today announced that it has redeemed all of its outstanding senior notes matured (the "Redemption") on July 31, 2022 (the "Maturity Date").
  • The redemption price included the principal amount of all outstanding Senior Notes of US$223,984,000 and the interest of US$8,343,404 accrued till the day before the Maturity Date.
  • The Company believes the Redemption will not have an adverse and material impact on its financial position.
  • Upon the completion of the Redemption, all senior notes have been cancelled and delisted from the official list of the Hong Kong Stock Exchange.

Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients

Retrieved on: 
Wednesday, August 3, 2022 - 9:50am

HANGZHOU and SHAOXING, China, Aug. 3, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ASC10, an oral drug candidate targeting RNA-dependent RNA polymerase (RdRp) for COVID-19, to conduct the Phase Ib clinical trial in mild-to-moderate COVID-19 patients. Ascletis will immediately initiate the clinical trial in patients to collect ASC10's clinical safety, pharmacokinetics and preliminary efficacy data.

Key Points: 
  • Ascletis will immediately initiate the clinical trial in patients to collect ASC10's clinical safety, pharmacokinetics and preliminary efficacy data.
  • ASC10 is an orally bioavailable double prodrug which has a new and differentiated chemical structure from the single prodrug molnupiravir.
  • ASC10 oral tablet formulation for the clinical study was developed with in-house proprietary technology of Ascletis.
  • FDA recommended that Ascletis directly conduct the first clinical study of ASC10 in mild-to-moderate COVID-19 patients rather than in healthy subjects.

Zhaoke Ophthalmology Completed Patient Enrollments for the Phase III Clinical Trials of the Myopia Progression Treatment Drug NVK002

Retrieved on: 
Wednesday, August 3, 2022 - 2:16am

The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.

Key Points: 
  • The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.
  • These early completions of patient recruitment across both trials, gives the company a strong headstart in moving towards its goal to lead the market in launching a myopia progression treatment drug.
  • Following this, a New Drug Application ("NDA") submission to the US Food and Drug Administration (the "FDA") is expected in 2023.
  • Dr. Li Xiaoyi (Benjamin), Chairman of the Board of Directors, Executive Director and CEO of Zhaoke Ophthalmology, said, "The early completion of the patient recruitment of NVK002's Phase III clinical trials marks another huge and exciting milestone for Zhaoke Ophthalmology.

Tims China and Easy Joy Open Three Tims Coffee Shops in Beijing

Retrieved on: 
Monday, August 1, 2022 - 2:40pm

SHANGHAI, China, Aug. 01, 2022 (GLOBE NEWSWIRE) -- TH International Limited, the exclusive operator of Tim Hortons coffee shops in China (Tims China), today announced the opening of three Tims Express coffee shops located within Easy Joy convenience stores in Beijing.

Key Points: 
  • SHANGHAI, China, Aug. 01, 2022 (GLOBE NEWSWIRE) -- TH International Limited, the exclusive operator of Tim Hortons coffee shops in China (Tims China), today announced the opening of three Tims Express coffee shops located within Easy Joy convenience stores in Beijing.
  • These openings are part of Tims China's collaboration with Easy Joy, China's largest convenience store chain, which was announced earlier this month.
  • The newly opened Tims China shops employ the new Tims Express format, a compact and efficient footprint that integrates easily into Easy Joy stores and exhibits Tims Chinas signature welcoming design.
  • Tims China offers freshly brewed coffee, tea and other beverages, bakery & sides, and sandwiches and is an emerging coffee champion in China.

Bragar Eagel & Squire, P.C. Is Investigating NIO, Generac, Cognyte, and TD and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, August 1, 2022 - 2:00am

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, NIO's American depositary receipt ("ADR") price fell $2.75 per ADR, or 15.17%, to close at $15.38 per ADR on May 5, 2022.
  • For more information on the TD investigation go to: https://bespc.com/cases/TD
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Linmon Media Proposed Listing on the Main Board of the Hong Kong Stock Exchange

Retrieved on: 
Friday, July 29, 2022 - 1:41am

HONG KONG, July 29, 2022 - (ACN Newswire) - A leading drama series production company in China - Linmon Media Limited ("Linmon Media" or the "Company", together with its subsidiaries, the "Group", stock code: 9857.HK), today announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange").

Key Points: 
  • HONG KONG, July 29, 2022 - (ACN Newswire) - A leading drama series production company in China - Linmon Media Limited ("Linmon Media" or the "Company", together with its subsidiaries, the "Group", stock code: 9857.HK), today announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange").
  • Linmon Media will open for Hong Kong Public Offering in Hong Kong at 9 a.m., July 29, 2022 (Friday), and close at 12:00 noon, August 3, 2022 (Wednesday).
  • Dealings in shares of Linmon Media on the Main Board of the Hong Kong Stock Exchange is expected to commence on August 10, 2022 (Wednesday).
  • This press release has not been reviewed or approved by The Stock Exchange of Hong Kong Limited or the Securities and Futures Commission of Hong Kong.